Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Green

Dermatology Marlton, NJ Medical Doctor

NPI 1104894872 CMS profile 94887

10000 Sagemore Dr Ste 10101, Marlton, NJ 08053

Open in the dashboard

General payments

$5,733

234 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Green of Marlton, NJ is reported in the CMS Open Payments database as having received $5,733 across 234 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,494 85
2024 General $1,037 67
2023 General $2,261 60
2022 General $790 19
2020 General $26 2
2019 General $125 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Green
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Justin Green were reported at $1,494. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Justin Green Dermatology median Middle half National median
2019 $125 $454 $129–$1,240 $163
2020 $26 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $790 $514 $143–$1,391 $149
2023 $2,261 $607 $159–$1,674 $160
2024 $1,037 $751 $204–$1,903 $164
2025 $1,494 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LEO Pharma Inc. $950 15 payments
  2. Sun Pharmaceutical Industries Inc. $618 19 payments
  3. AbbVie, Inc. $605 51 payments
  4. LEO Pharma AS $450 1 payment
  5. Janssen Biotech, Inc. $424 12 payments
  6. E.R. Squibb & Sons, L.L.C. $306 11 payments
  7. Pfizer Inc. $301 11 payments
  8. Amgen Inc. $258 10 payments
  9. Regeneron Healthcare Solutions, Inc. $239 9 payments
  10. Novartis Pharmaceuticals Corporation $221 12 payments
  11. Other $1,361 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,069 225 payments
  2. Consulting Fee $1,200 2 payments
  3. Education $464 7 payments
Products named General payments · program years 2019–2025
  1. ADBRY $950 15 payments
  2. TREMFYA $424 12 payments
  3. RINVOQ $359 25 payments
  4. SOTYKTU $306 11 payments
  5. CIBINQO $286 10 payments
  6. Otezla $258 10 payments
  7. COSENTYX $208 11 payments
  8. Bimzelx $174 10 payments
  9. OPZELURA $171 9 payments
  10. DUPIXENT $151 4 payments
  11. Other $2,167 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,843

Median for Dermatology: 534

Drug cost

$1,460,741

Median for Dermatology: $67,151

Branded share of claims

19.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 30 $604,514
Dupixent Pen Dupilumab Brand 51 $265,797
Otezla Apremilast Brand 38 $180,838
Dupixent Syringe Dupilumab Brand 39 $145,846
Taltz Autoinjector Ixekizumab Brand 17 $113,535
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $102,794
Ketoconazole Generic 269 $4,541
Clobetasol Propionate Generic 82 $4,175
Metronidazole Generic 82 $3,909
Betamethasone Dipropionate Generic 75 $2,711

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$622,522

Of which drugs: $321,343

Medicare patients

1,160

Average age 74

Services billed

9,193

573 women, 587 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 47%
Ischemic heart disease 27%
Diabetes 24%
Chronic kidney disease 19%
Cancer 18%
Osteoporosis 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tildrakizumab, 1 mg J3245 Office 11 2,900 $310,408
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 24 35 $10,860
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 23 37 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $94
$94 14 —
RINVOQ
  • AbbVie, Inc. $83
$83 — —
SKYRIZI
  • AbbVie, Inc. $80
$80 30 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $70
$70 — —
OPZELURA
  • Incyte Corporation $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record